Estetrol (E4), the first NEST™
Due to perceived safety and health concerns linked to hormone-related therapies, many women continue to avoid treatment for menopause symptoms or contraceptive solutions. Studies also underline the unmet need today for an estrogen with an improved benefit/risk profile. Preclinical and clinical research to date indicate that E4 could address this unmet need.
Estetrol (E4) is the first NEST™ : Native Estrogen with Selective action in Tissues. Because of its unique mode of action, Mithra believes E4 has the potential to transform the Women’s Health Market, providing an improved side effect profile over current estrogens in key areas including oral contraception and menopause.
Today, Mithra is focused on the development of three late-stage E4-based products : Estelle®, a 5th generation oral contraceptive, PeriNestaTM, the first complete oral treatment for perimenopause and Donesta®, a next generation hormone therapy for VMS in menopause.